Avacta Group Plc (AVCTF)
| Previous Close | 0.6990 |
| Open | 0.6990 |
| Bid | 0.7777 x 0 |
| Ask | 0.8404 x 0 |
| Day's Range | 0.6990 - 0.6990 |
| 52 Week Range | 0.4786 - 2.1700 |
| Volume | |
| Avg. Volume | 257 |
| Market Cap | 301.094M |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | Sep 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAvacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology
Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology LONDON – Oct. 21, 2024 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the initiation of an artificial intelligence (AI)-focused collaboration with Tempus AI, Inc. (Nasdaq: TEM), a technology comp
- GlobeNewswire
Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform
Avacta Group plc ("Avacta" or "the Group" or "the Company")Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform London, Oct. 17, 2024 – Avacta Group plc (AIM: AVCT), a life sciences company developing innovative targeted oncology drugs, today announces the addition of two novel preclinical oncology assets, AVA6103 and AVA7100, to its pipeline of pre|CISION®-enabled drug conjugates. Avacta is developing a portfolio of pre|CISION® product candidates that are d
- GlobeNewswire
Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer
Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer London, Oct. 15, 2024 – Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announced the appointment of seasoned scientific leader Michelle Morrow, PhD as Chief Scientific Officer with effect from November 4, 2024. Dr. Morrow brings nearly 20 years’ experience in oncology t
